Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Novartis AG is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences Inc. in a bid to boost its drug ...

Novartis AG (NVS) has made a takeover approach for San Diego-headquartered Avidity Biosciences (RNA), Financial Times ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Oregon passed a new law this year requiring drug manufacturers to sell more of their medications at a discount.

After weeks of working with U.S. officials to try to avoid hefty tariffs on Swiss goods, negotiators from Switzerland got ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...